Phase 3 Recruiting NIH
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 3 Recruiting NIH
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06498635
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in North Dakota: - Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in North Dakota: - Research Site — Grand Forks, North Dakota
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in North Dakota: - Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0063) — Fargo, North Dakota
- Altru Health System ( Site 0040) — Grand Forks, North Dakota
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in North Dakota: - Sanford Bismarck Medical Center — Bismarck, North Dakota
- Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
- Sanford Broadway Medical Center — Fargo, North Dakota
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in North Dakota: - Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immun…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06731907
Sites in North Dakota: - Sanford Fargo Medical Center ( Site 0039) — Fargo, North Dakota
Phase 2 Recruiting Industry
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gen…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07252739
Sites in North Dakota: - Sanford Health Roger Maris Cancer Center ( Site 0039) — Fargo, North Dakota
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in North Dakota: - Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
NA Recruiting Academic/Other
Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to te…
Sponsor: University of North Dakota
NCT ID: NCT07591389
Sites in North Dakota: - University of North Dakota Center for Family Medicine, Bismarck Clinic — Bismarck, North Dakota
- University of North Dakota Center for Family Medicine, Minot Clinic — Minot, North Dakota